Lisinopril & Trimethoprim-Sulfamethoxazole Interaction

The combination of lisinopril and trimethoprim-sulfamethoxazole (TMP-SMX, sold as Bactrim or Septra) significantly increases the risk of hyperkalemia — dangerously elevated potassium levels that can cause fatal cardiac arrhythmias ^[1]. ACE inhibitors like lisinopril raise serum potassium by blocking aldosterone secretion, and trimethoprim independently acts as a potassium-sparing diuretic by blocking epithelial sodium channels (ENaC) in the distal nephron, mimicking the effect of amiloride ^[2]. A landmark population-based study found that TMP-SMX use in patients on ACE inhibitors or ARBs was associated with a 6.7-fold increased risk of hospitalization for hyperkalemia compared to other antibiotics ^[1].

This interaction is especially concerning because TMP-SMX is one of the most commonly prescribed antibiotics for urinary tract infections and other common infections, and millions of patients take ACE inhibitors for hypertension and heart failure ^[3]. The hyperkalemia can develop rapidly — sometimes within 3-5 days of starting TMP-SMX — and may present as a medical emergency with cardiac conduction abnormalities ^[1].

Lisinopril inhibits angiotensin-converting enzyme (ACE), reducing the conversion of angiotensin I to angiotensin II ^[3]. Because angiotensin II is a primary stimulus for aldosterone release, ACE inhibition results in decreased aldosterone levels, which reduces potassium excretion by the principal cells of the cortical collecting duct ^[3]. The trimethoprim component of TMP-SMX blocks the epithelial sodium channel (ENaC) in the distal nephron and collecting duct at therapeutic concentrations, directly inhibiting sodium reabsorption and potassium secretion — pharmacologically identical to the mechanism of the potassium-sparing diuretic amiloride ^[2]. At standard doses, trimethoprim inhibits approximately 30-50% of ENaC-mediated potassium excretion ^[2]. The dual impairment of potassium homeostasis — reduced aldosterone-mediated excretion (from lisinopril) plus direct blockade of tubular potassium secretion (from trimethoprim) — can produce rapid and severe potassium accumulation, particularly in patients with pre-existing renal impairment, diabetes, or other risk factors for hyperkalemia ^[1].

A population-based study of over 30,000 patients found that those prescribed TMP-SMX while on an ACE inhibitor had a 6.7-fold increased odds of hyperkalemia-related hospitalization and a 1.38-fold increased odds of sudden death within 14 days, compared to patients prescribed amoxicillin ^[1]. Another study found that 21% of patients on ACE inhibitors who received TMP-SMX developed potassium levels above 5.0 mEq/L, with 6% developing severe hyperkalemia (>6.0 mEq/L) ^[2]. Risk factors that amplify this interaction include: chronic kidney disease (eGFR <60), diabetes mellitus, heart failure, concurrent use of other potassium-raising medications (potassium supplements, spironolactone, NSAIDs), advanced age (>65 years), and dehydration ^[1]. Hyperkalemia above 6.0-6.5 mEq/L can cause peaked T waves, widened QRS complexes, loss of P waves, ventricular fibrillation, and cardiac arrest ^[3]. The onset is typically within 3-7 days of starting TMP-SMX, coinciding with accumulation of trimethoprim to steady-state levels ^[2].

Use alternative antibiotics in patients on ACE inhibitors whenever possible ^[1]. For urinary tract infections, nitrofurantoin, cephalexin, or fosfomycin are appropriate alternatives that do not raise potassium ^[2]. If TMP-SMX is the only appropriate antibiotic (e.g., for Pneumocystis jirovecii pneumonia prophylaxis or treatment, or for specific resistant organisms), check serum potassium and renal function before starting, and recheck potassium at 3-5 days ^[1]. Consider temporarily reducing or holding the ACE inhibitor dose during the TMP-SMX course, under medical supervision ^[3]. Advise patients to avoid high-potassium foods (bananas, oranges, potatoes, tomatoes, salt substitutes) during concurrent therapy ^[2]. Hold potassium supplements and discontinue spironolactone or other potassium-sparing agents during TMP-SMX use ^[1]. If potassium exceeds 5.5 mEq/L, discontinue TMP-SMX and manage hyperkalemia with standard protocols (calcium gluconate for cardiac stabilization, insulin-glucose, sodium polystyrene sulfonate or patiromer for potassium reduction) ^[3].

Check serum potassium and serum creatinine before starting TMP-SMX in any patient on an ACE inhibitor or ARB ^[1]. Repeat potassium at 3-5 days after starting TMP-SMX — this is the critical window when hyperkalemia typically develops ^[1]. If the TMP-SMX course exceeds 7 days, check potassium weekly ^[2]. Obtain an ECG if potassium exceeds 5.5 mEq/L or if the patient reports symptoms of hyperkalemia: muscle weakness, fatigue, paresthesias, palpitations, nausea, or a feeling of chest heaviness ^[3]. Monitor urine output, as oliguria can accelerate potassium accumulation ^[2]. After completing the TMP-SMX course, recheck potassium at 3-5 days to confirm normalization, particularly in patients with CKD ^[1].

For uncomplicated urinary tract infections, nitrofurantoin (Macrobid) is effective against common uropathogens without potassium-raising effects ^[2]. Cephalexin (Keflex) provides broad gram-positive and some gram-negative coverage without affecting renal potassium handling ^[1]. Fosfomycin (Monurol) is a single-dose option for uncomplicated UTIs in women ^[2]. For skin and soft tissue infections, cephalexin, clindamycin, or doxycycline can substitute for TMP-SMX in most cases ^[3]. For MRSA coverage specifically, doxycycline or clindamycin may be appropriate depending on local resistance patterns ^[2]. When TMP-SMX is required for Pneumocystis prophylaxis in immunocompromised patients, dapsone or atovaquone are alternatives, though they have their own side effect profiles ^[3]. Always verify antibiotic susceptibility when possible to guide selection ^[1].